Artwork

Content provided by Mayo Clinic Laboratories. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mayo Clinic Laboratories or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Tests Aid Diagnosis of Cancer-Associated Neurological Disorders: Divyanshu Dubey, M.B.B.S.

14:27
 
Share
 

Manage episode 421894172 series 2908385
Content provided by Mayo Clinic Laboratories. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mayo Clinic Laboratories or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 assays facilitate care for central nervous system disorders triggered by cancer. Early diagnosis and treatment are important for managing disabling neurological symptoms and malignancy.

(00:32)
Could you tell us a bit about your background and your role at Mayo Clinic?

(01:26)
How do the tests that are coming live relate to the larger disease state of neurological disorders?

(02:44)
Can you share a little bit about the methodology we're using for these particular biomarkers?

(05:15)
How was PDE10A discovered?

(06:48)
Anything you would add?

(07:50)
Remind us which phenotype-specific assays these biomarkers are being added to, and how physicians should determine whether this testing is appropriate?

(09:55)
What does early detection of these biomarkers mean for the patient's prognosis, diagnosis, treatment, etc.?

(12:33)
What are you most excited about with the launch of these tests?

  continue reading

310 episodes

Artwork
iconShare
 
Manage episode 421894172 series 2908385
Content provided by Mayo Clinic Laboratories. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mayo Clinic Laboratories or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 assays facilitate care for central nervous system disorders triggered by cancer. Early diagnosis and treatment are important for managing disabling neurological symptoms and malignancy.

(00:32)
Could you tell us a bit about your background and your role at Mayo Clinic?

(01:26)
How do the tests that are coming live relate to the larger disease state of neurological disorders?

(02:44)
Can you share a little bit about the methodology we're using for these particular biomarkers?

(05:15)
How was PDE10A discovered?

(06:48)
Anything you would add?

(07:50)
Remind us which phenotype-specific assays these biomarkers are being added to, and how physicians should determine whether this testing is appropriate?

(09:55)
What does early detection of these biomarkers mean for the patient's prognosis, diagnosis, treatment, etc.?

(12:33)
What are you most excited about with the launch of these tests?

  continue reading

310 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide